March 1, 2023
5:00 PM – 6:00 PM CET
11:00 AM – 12:00 PM EST
8:00 AM – 9:00 AM PST
Objectives:
- To improve the understanding of clinicians in identifying which CDK 4/6 treatment to choose in taking a shared decision approach
- The patient experience of targeted therapy toxicities and how it impacts quality of life, adherence, and disease outcomes
- Identify innovative strategies to optimally manage related toxicities with CDK4/6 inhibitors in patients with breast cancer
Learner Outcomes:
- How to make personalized treatment decisions for patients with hormone receptor positive breast cancer who are candidates for CDK 4/6 inhibitors
- How to improve supportive care strategies for patients with breast cancer who are undergoing targeted therapy
- Address in knowledge in management and how to best deliver multi D care for cancer survivors of all stages
Speakers:
- Prof Maryam Lustberg (Session Chair)
- Prof Hope Rugo
- Dr Kelly Shanahan (Patient Advocate)
- Dr Paolo Tarantino
This webinar was made possible by an unrestricted educational grant provided by Pfizer
